Shanghai June 18, 2024. e-BLOT Life Sciences (Shanghai) Co., Ltd. (e-BLOT) successfully signed a framework agreement with BIOKÉ / Cell Signaling Technology (CST) Europe B.V., marking the first step in collaboration between the two companies in the life sciences field.
e-BLOT, as a leading supplier of biomedical innovation tools and solutions, has earned widespread recognition in the industry for its cutting-edge technology and excellent product quality since its inception. Imaging technology plays a crucial role in the life and health sector, with approximately 30% of experiments or diagnostics relying on imaging technology for accurate judgments or conclusions. The Touch Imager electronic blot imaging system provided by e-BLOT revolutionizes traditional lens imaging technology by pioneering the application of contact imaging technology to the imaging field, ushering in a new era of chemiluminescence imaging. This technology significantly improves imaging quality and efficiency with sensitivity and quantitative dynamic range two orders of magnitude higher than traditional cold CCD technology. This product not only enjoys high brand recognition in the domestic market but is also exported to numerous countries, including the United States, Switzerland, Sweden, Japan, and South Korea, and is highly favored by academic, pharmaceutical, and biotechnology laboratories. Additionally, over 300 related papers have been published on this product (with the highest impact factor being 64.8).
BIOKÉ (a business unit of Cell Signaling Technology) was founded in 2004, BIOKÉ is a company with knowledgeable and experienced people and provides innovative technologies with the highest quality in the life science market throughout Europe. Their portfolio consists of unique and best-in-class reagents, consumables and instruments for sample preparation & analysis, next-generation sequencing (NGS), cloning and functional analysis, single cell research and RNA technologies. Their dedicated team of enthusiastic people provides customized solutions to customers, including service support – not as a contractor, but as a knowledge partner. In July 2009 Cell Signaling Technology, Inc. (CST) acquired BIOKÉ BV and BIOKÉ became a business unit of Cell Signaling Technology. BIOKÉ holds offices in Leiden, the Netherlands.
Cell Signaling Technology (CST) is a unique and prestigious life sciences company founded, owned, and operated by active research scientists. Over the past 25 years, it has achieved the highest standards in product and service quality, technological innovation, and scientific rigor. CST is dedicated to providing the world’s highest quality research and diagnostic products to advance biological understanding and achieve personalized medicine. The antibodies provided by CST adhere to the Antibody Validation Mark, which involves six complementary strategies to ensure functionality, specificity, and sensitivity. These antibodies play an indispensable role in research across multiple fields, including oncology, immunology, and neurobiology.
The framework agreement signed aims to lay the foundation for potential collaboration between the two parties in the European region. Mr. Zhang, the founder of e-BLOT, is full of expectations for this collaboration. He stated, “We are very pleased with the opportunity to cooperate with BIOKÉ / CST and hope to promote this collaboration by leveraging our mutual strengths.”Koos Kranenborg, the founder of BIOKÉ, is excited about the collaboration. He expressed, “We are eager to provide our customers with the e-BLOTs Touch Imager. This cutting-edge instrument offers exceptional data quality and enhanced throughput, ensuring our customers receive top-notch results.” This agreement not only provides guidance for further detailed negotiations and potential collaboration but also opens new possibilities for the future development of both companies. As the collaboration deepens, the two companies will focus on multiple areas to enhance strategic complementarity, aiming to achieve more results in the life sciences field. This collaboration is expected not only to promote in-depth exchanges in technology research and development, market expansion, and investment and financing but also to bring new development opportunities to the entire life sciences industry.
